The most common neurodegenerative pathologies underlying age associated cognitive decline, mild cognitive impairment (MCI) and dementia are Alzheimer's disease (AD) and Lewy body disease (LBD) pathologies. Evidence from proton MR Spectroscopy (MRS) and diffusion tensor MRI (DTI) suggest that these techniques are sensitive to early events in the neurodegenerative disease process at the cellular or molecular level. These MR markers may be more sensitive to degenerative changes preceding atrophy, and may provide additional information over structural MRI especially early in the disease course. Although the recent findings in clinically diagnosed patients are promising, the pathologic underpinnings of MRS and DTI alterations in neurodegenerative dementia are not well understood. Our goal is to validate MRS and DTI measures as surrogate markers of AD and LBD pathologies, because they are the most common neurodegenerative changes found in the elderly population. Our objective is to identify the biological correlates of antemortem MRS and DTI changes in specific cortical regions and white matter tracts associated with the paired helical filament (PHF)-tau, amyloid-? and alpha-synuclein mediated pathology. The overarching goal is to translate the MR markers into clinically valid measures of AD and LBD pathologies. The antemortem MRS and DTI changes associated with postmortem PHF-tau, amyloid-b and alpha-synuclein mediated neurodegenerative pathology will be identified using ROI-based quantitative methods for correlating antemortem imaging with postmortem histology. Finally, we will translate MRS and DTI markers to clinically valid measures of pathological severity.
As an outcome of the proposed investigations, we will identify the pathologic basis of magnetic resonance spectroscopy and diffusion tensor imaging changes associated with neurodegeneration in a spectrum of Alzheimer's disease and Lewy body disease pathologies. The proposal is relevant because, with the development of disease modifying treatments, imaging markers of neurodegenerative dementia pathologies will be required for early diagnosis, treatment decisions and monitoring treatment response.
|Zhang, Bing; Ferman, Tanis J; Boeve, Bradley F et al. (2015) MRS in mild cognitive impairment: early differentiation of dementia with Lewy bodies and Alzheimer's disease. J Neuroimaging 25:269-74|
|Nedelska, Zuzana; Ferman, Tanis J; Boeve, Bradley F et al. (2015) Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiol Aging 36:452-61|
|Raman, Mekala R; Wiste, Heather J; Senjem, Matthew L et al. (2014) Spontaneous amyloid-related imaging abnormalities in a cognitively normal adult. Neurology 83:1771-2|
|Kantarci, K (2014) Molecular imaging of Alzheimer disease pathology. AJNR Am J Neuroradiol 35:S12-7|
|Graff-Radford, Jonathan; Murray, Melissa E; Lowe, Val J et al. (2014) Dementia with Lewy bodies: basis of cingulate island sign. Neurology 83:801-9|
|Graff-Radford, Jonathan; Boeve, Bradley F; Murray, Melissa E et al. (2014) Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. Neurobiol Aging 35:1483-90|
|Schwarz, Christopher G; Reid, Robert I; Gunter, Jeffrey L et al. (2014) Improved DTI registration allows voxel-based analysis that outperforms tract-based spatial statistics. Neuroimage 94:65-78|
|Roberts, Rosebud O; Knopman, David S; Przybelski, Scott A et al. (2014) Association of type 2 diabetes with brain atrophy and cognitive impairment. Neurology 82:1132-41|
|Kantarci, Kejal; Maki, Pauline M (2014) Past hormone therapy in older women: does the brain recover from adverse effects? Neurology 82:380-1|
|Jack Jr, Clifford R; Wiste, Heather J; Weigand, Stephen D et al. (2014) Age-specific population frequencies of cerebral ?-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol 13:997-1005|
Showing the most recent 10 out of 18 publications